Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF614
- Development stage
- Phase 3
- Lead developer
- Ensysce Biosciences
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
PF614 is an orally available, extended-release prodrug of oxycodone developed using Trypsin-Activated Abuse Protection (TAAP) technology. It is designed to treat severe and/or chronic pain by releasing oxycodone only after activation by digestive enzyme trypsin in the small intestine. This two-step activation process provides abuse deterrence by preventing immediate release if the drug is chewed, snorted, or otherwise manipulated. The pharmacokinetic profile of PF614 matches that of standard extended-release oxycodone formulations but with significantly lower "Drug Liking" scores among recreational users. The drug aims to provide effective pain relief while reducing risks associated with opioid misuse and abuse[1][2][3][5][7].
- Brand names
- BIO-MD PF614ER Oxycodone Bio-MD System
- Other names
- Oxycodone prodrug extended release - Ensysce BiosciencesTAAP oxycodone
02
Targets
MOR (Mu opioid receptor)
Beyond the preview
Go deeper on PF614.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF614.